

**Figure S1. Detailed schematic of the model**



 **Figure S2. Markov traces for BRCA positive patients receiving olaparib treatment**

****

**Figure S3. Markov traces for BRCA carriers receiving NHA treatment**



**Figure S4. Markov traces for BRCA negative/non-carriers receiving NHA treatment**

**Figure S5. Change in incremental cost-effectiveness ratio (ICER) with reduction in olaparib cost.**